Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2017: PRESS-RELEASE: Paris-November 16, 2017:BMSystems is selected to pitch at the “Translational Neurosciences Conference” organized by “NeurATRIS” and supported by “eartis” the European Infrastructure For Translational Medicine, comprising more than 80 leading European Institutes.

  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
     
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
     
  • 2017: ANNOUNCEMENT: Paris September 7, 2017: The future of Medicine: Bio-Modeling Systems invited to present at the Summer Universities of Fédération Hospitalière de France
     
  • 2017: ANNOUNCEMENT: Belgium August 26-27, 2017: BMSystems selected to meet Wallonia life Sciences Companies and is invited to the Spa-Francorchamps Formula 1 Race. Great place for top meeting!

  • 2017: ANNOUNCEMENT: Paris July 4, 2017. BMSystems was invited to present at the Conference INSEAD Alumni at BCG Paris Office: Everything you always wanted to know about Digital Health revolution “big promises” but were afraid to ask!

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems was invited at the France-India healthcare Summit to present its Computer Augmented Deductive Intelligence platform and its operational successes

  • 2017: ANNOUNCEMENT: Paris January 17, 2017: BMSytems invited to present its collaborative success story with CEA life Sciences at the 10 years anniversary of Medicen Paris Region Health cluster

  • 2017: Happy New Year: Our 8 Resolutions for 2017 to be ready for the upcoming bubble explosion! - Bonne Année: Nos 8 Résolutions pour 2017
     
  • 2016: INTERVIEW (Post LinkedIn FR avec explications): "Drug Discovery and health Big Data. The enormous Bubble will explode.” (Post LinkedIn ENG with all the explanations)  Manuel GEA, CEO of BMSystems in Biotech & Finances the leading biotech sector information letter

  • 2016: ANNOUNCEMENT: Paris October 5, 2016: BMSystems' CEO invited to present its digital-biology strategy and achievements at the inaugural session of Medicen Paris Region 10th years anniversary

  • 2016: PRESS RELEASE: Paris September 5, 2016: BMSystems selected to present CADI Discovery at the Connexion R&D conference organized by COSMETIC-VALLEY the leading Perfumery & Cosmetic cluster in France.

  • 2016: ANNOUNCEMENT August 1, 2016: BIO-MODELING SYSTEMS' novel Parkinson's therapy mentioned in a Report Covering 179 Companies. A new recognition of CADI Discovery capability to generate novel therapeutic strategies in complex human diseases of which CNS

  • 2016: Updated: Inaugural Presentation Bio-Entrepreneur 2015: The future will be digital and biology, but who will lead? Google? Watson? Alone or MDs, Physiologists, Biologists educating and mastering them combining diagnostics, therapies, connected devices and IT technologies?
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

BMSystems history

1989 -1993 Dr. Iris is Group Leader at the CEPH in Paris

  • The CEPH is a Research Institute founded and lead by Nobel laureate Prof. Jean Dausset.
  • Develops methods for high-throughput (HT) sequencing & data integration.
  • Realizes that the links between genome & biological processes are non-linear.
  • One gene = several proteins = multiple interactions = many context-dependent functions.

1993 -1996 Dr. Iris creates & leads Millennium Pharmaceuticals' (USA) HT Sequencing Unit

  • He undertakes the first attempts to carry-out physiological modeling via large scale data integration.
  • He invents & develops the basic tools and methods required for Integrative Biology.
  • Successful completion of two models, leading to the discovery of the UCP2 and EST1 genes and their roles in obesity and hyperglycemia.
  • He realizes that since published information is:
    • incomplete (to an unknown extent),
    • slanted (to an unknown extent),and often
    • incorrect (to an unknown extent).
  • Methodologies to access/generate complementary unbiased information are required

1996-2001 - Dr. Iris is co-founder and C.S.O. of ValiGen SA in Paris

  • He invents, develops and patents 4 new differential gene-expression and genotyping technologies.
  • He invents and develops the computerized data gathering, data mining, clustering and integration tools & technologies necessary for the industrial development of  Integrative Biology / Systems Biology (European "Eureka" grant: 18.6 M Euros).
  • He finalizes the Bio-Graph™ analytical platform based on the "positive selection" concept.
  • He develops the Tamoxifen Resistance model with Bio-Graph™.
  • He identifies the limitations of this analytical platform.

1999-2001 - Dr. Iris meets Mr. M.Gea and Dr. G.Dine

  • Dr. Iris meets M.Gea and Prof. G.Dine, founding members of Centrale-Santé.
  • Dr. François Iris becomes a member of Centrale-Santé's Directorate, the Healthcare & Biotech Think Tank of the Centrale's alumni's Association.
  • He decides to abandon the Bio-Graph™  platform and starts working on a second Generation analytical platform (CADI™) based on the negative selection concept.
  • He starts to work on the first version of the Creutzfeldt-Jakob Disease model. 

2002-2003 -  Dr. Iris, M. Gea and Dr. Dine initiate the BMSystems project

  • Conception of the first European private biotech company specialized in Predictive Integrative biology / Systems Biology.
  • Paul-Henri Lampe, and Pablo Santamaria, members of Centrale-Santé Think Tank, decide to join the project.
  • Development of the CADI™ analytical platform.
  • Four new models completed (FGF4-driven fibroblast differentiation, hypercholesterolemia, Chronic Fatigue Syndrome, Creutzfeldt Jakob disease) two of which are undergoing independent biological evaluation.

2004 - The company is created and starts business operations

  •  Independent Private Company incorporated in 2004. 100% owned by its founders.
  • Profitable since 2006, thanks to our recurrent clients.
  • We only sell the results of the R&D programs, not our proprietary technologies.
  • 100% biology driven company focused on discovery, and critical high impact decisions making
  • A unique proprietary CADI™ Knowledge Database of mechanisms & interactions.
  • Not domain-dependent, but information-dependent. Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health,
  • Highly productive 24 vFTE* of which 9 vFTE on CADI™ Discovery programs only.
  • Strong & long term strategic R&D collaborations (>100 people collaborating).
  • Dual business model : Contractual or Collaborative R&D programs.
  • External valorization of our collaborative R&D programs through out-licensing or spin-off.
  • Outstanding internal pipeline of programs ready for collaborations.
  • 1 therapeutic spin-off and 1 exclusive out-licence, 4 issued patents, 10 publications.
Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers ?>